Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

dc.contributor.authors	Bayoglu IV, Kucukzeybek BB, Kucukzeybek Y, Varol U, Yildiz I, Alacacioglu A, Akyol M, Demir L, Dirican A, Yildiz Y, Salman T, Tarhan MO
dc.date.accessioned	2020-02-27T08:42:40Z
dc.date.available	2020-02-27T08:42:40Z
dc.date.issued	2015
dc.identifier.citation	Bayoglu IV, Kucukzeybek BB, Kucukzeybek Y, Varol U, Yildiz I, Alacacioglu A, Akyol M, Demir L, Dirican A, Yildiz Y, Salman T, Tarhan MO (2015). Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers. Biomed Pharmacother, 70, 5-190
dc.identifier.uri	https://doi.org/10.1016/j.biopha.2015.01.019
dc.identifier.uri	https://hdl.handle.net/20.500.12619/66766
dc.title	Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers
dc.identifier.volume	70
dc.identifier.startpage	190
dc.identifier.endpage	5
dc.contributor.department	Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü
dc.contributor.saüauthor	Bayoğlu, İbrahim Vedat
dc.relation.journal	Biomed Pharmacother
dc.identifier.doi	10.1016/j.biopha.2015.01.019
dc.contributor.author	Bayoğlu, İbrahim Vedat